ClinicalTrials.gg
CompletedNCT02410200FOCUSUpdated Oct 23, 2017Results posted

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

A Phase 2 interventional study of dimethyl fumarate in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Completed at 12 sites in 10 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-10-23.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
15th of 22
22 · median 61
Started
2015
with 5 others
Phase 2
2 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 15th largest by enrollment, is one of 6 that started in 2015, is one of 2 in phase 2, and was the 11th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of BG00012 (dimethyl fumarate) on brain magnetic resonance imaging (MRI) lesions in pediatric participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are to characterize the pharmacokinetics of BG00012 in pediatric participants with RRMS and to evaluate the safety and tolerability of BG00012 in pediatric participants with RRMS.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Pediatrics
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability of parents or legal guardians to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information in accordance with national and local subject privacy regulations. Subjects will provide assent in addition to the parent or legal guardian, as appropriate, as per local regulations.
  • Must have a body weight of ≥30 kg at Screening and Day 1.
  • Must have a diagnosis of RRMS according to McDonald criteria for MS (2010) [Polman 2011] and International Pediatric Multiple Sclerosis (MS) Study Group criteria for pediatric MS (2013) [Krupp 2013].

Key Exclusion Criteria:

  • Primary progressive, secondary progressive, or progressive relapsing MS (as defined by [Lublin and Reingold 1996]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses but are distinguished from relapsing-remitting subjects by the lack of clinically stable periods or clinical improvement.
  • Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic disorders (e.g., Sjögren disease, lupus erythematosus, and neuromyelitis optica), metabolic disorders (e.g., dystrophies), and infectious disorders.
  • History of severe allergic or anaphylactic reactions or known drug to dimethyl fumarate or fumaric acid esters.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    BG00012

    Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.

    Drug: dimethyl fumarate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period

    Time frame: Baseline Period (Week -8 to Day 0), On-Treatment Assessment Period (Week 16 to Week 24)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 8

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Day 8

  3. Apparent Clearance (CL/F)

    Time frame: Day 8

  4. Apparent Volume of Distribution (V/F)

    Time frame: Day 8

  5. Half-Life Lambda z

    Time frame: Day 8

  6. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)

    Time frame: Day 8

  7. Number of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.

    Time frame: Up to Week 28

07

Results

Posted Apr 28, 2017

Participant flow

Participant flow — Overall Study
MilestoneBG00012
Started22
Completed20
Not completed2
Withdrew: Adverse event2

Outcome measures

PrimaryChange in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period
Time frame:
Baseline Period (Week -8 to Day 0), On-Treatment Assessment Period (Week 16 to Week 24)
Reported as:
Mean · lesions
Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period
lesionsBG00012
Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period-7.9 ± 16.23
Statistical analysis
  • BG00012 · Wilcoxon Signed Rank test · p = 0.0090
SecondaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Day 8
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLBG00012
Maximum Observed Plasma Concentration (Cmax)1998.62 ± 1286.467
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Day 8
Reported as:
Mean · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hoursBG00012
Time to Reach Maximum Observed Plasma Concentration (Tmax)4.20 ± 1.543
SecondaryApparent Clearance (CL/F)
Time frame:
Day 8
Reported as:
Mean · L/h
Apparent Clearance (CL/F)
L/hBG00012
Apparent Clearance (CL/F)74.45 ± 30.185
SecondaryApparent Volume of Distribution (V/F)
Time frame:
Day 8
Reported as:
Mean · L
Apparent Volume of Distribution (V/F)
LBG00012
Apparent Volume of Distribution (V/F)98.19 ± 91.679
SecondaryHalf-Life Lambda z
Time frame:
Day 8
Reported as:
Mean · hours
Half-Life Lambda z
hoursBG00012
Half-Life Lambda z0.84 ± 0.408
SecondaryArea Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)
Time frame:
Day 8
Reported as:
Mean · h*mcg/mL
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)
h*mcg/mLBG00012
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)3630.52 ± 1153.768
SecondaryNumber of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.

Time frame:
Up to Week 28
Reported as:
Number · participants
Number of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsBG00012
Any event20
Moderate or severe event7
Severe event1
Event related to BG0001216
Serious event5
Serious event related to BG000120
Discontinued treatment due to an event2
Withdrew from study due to an event2

Adverse events

Collected over From first dose of study drug through end of treatment period (Week 24 ±7 days) plus 4 weeks follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BG00012—5/22 (22.7%)19/22 (86.4%)
Most frequent serious events
Most frequent serious events
EventBG00012
Multiple sclerosis relapseNervous system disorders4/22
VertigoEar and labyrinth disorders1/22
Most frequent other events
Showing 10 of 17
Most frequent other events
EventBG00012
FlushingVascular disorders10/22
Multiple sclerosis relapseNervous system disorders7/22
Abdominal painGastrointestinal disorders6/22
Abdominal pain upperGastrointestinal disorders4/22
NauseaGastrointestinal disorders4/22
HeadacheNervous system disorders4/22
VomitingGastrointestinal disorders3/22
FatigueGeneral disorders3/22
CoughRespiratory, thoracic and mediastinal disorders3/22
VertigoEar and labyrinth disorders2/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)BG00012
Mean15.8 ± 1.18
Sex: Female, Male
Sex: Female, Male(Participants)BG00012
Female14
Male8
08

Study locations

12 sites
  • Research Site
    San Bernardino, California 92408, United States
  • Research Site
    Gent, B-9000, Belgium
  • Research Site
    Sofia, B-1113, Bulgaria
  • Research Site
    Hradec kralove, 500 05, Czechia
  • Research Site
    Munchen, Bayern 80337, Germany
  • Research Site
    Gottingen, Niedersachsen 37075, Germany
  • Research Site
    Dasman, Kuwait City 15462, Kuwait
  • Research Site
    Riga, LV-1004, Latvia
  • Research Site
    Beirut, 1107 2020, Lebanon
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Poznan, 60-355, Poland
  • Research Site
    Ankara, 06100, Turkey
09

References and documents

Publications

  • Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). Pediatr Neurol. 2018 Jun;83:19-24. doi: 10.1016/j.pediatrneurol.2018.03.007. Epub 2018 Mar 22. PubMed 29681490 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Sep 2016, 11 months.

Results were first posted in Apr 2017, 7 months after primary completion.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2015
First posted
Apr 7, 2015
StartActual
Sep 30, 2015
Primary completionActual
Sep 23, 2016
CompletionActual
Sep 23, 2016
Results first posted
Apr 28, 2017
Last update
Oct 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02410200
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 7, 2015
Start date
Sep 30, 2015
Primary completion
Sep 23, 2016
Completion
Sep 23, 2016
Results posted
Apr 28, 2017
Last update
Oct 23, 2017

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion